AstraZeneca’s Q1 product sales declined 10% (3% at CER) yoy to $5.7bn. Total revenue was helped by an accounting change to include co-commercialisation income (earlier shown as other income) as part of the revenue. Generic erosion of once-leading drugs - Nexium, Crestor, Symbicort, Seroquel - along with the decline in Synagis have weighed on the growth exhibited by the newer drugs. Adjusted EBIT was negatively impacted by a c.17% increase in R&D efforts (thanks to the multitude of o
16 Jun 2015
R&D’s silver lining in otherwise difficult phase
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
R&D’s silver lining in otherwise difficult phase
AstraZeneca PLC (AZN:LON) | 12,010 80947.4 5.9% | Mkt Cap: 186,183m
- Published:
16 Jun 2015 -
Author:
Kamla Singh -
Pages:
3
AstraZeneca’s Q1 product sales declined 10% (3% at CER) yoy to $5.7bn. Total revenue was helped by an accounting change to include co-commercialisation income (earlier shown as other income) as part of the revenue. Generic erosion of once-leading drugs - Nexium, Crestor, Symbicort, Seroquel - along with the decline in Synagis have weighed on the growth exhibited by the newer drugs. Adjusted EBIT was negatively impacted by a c.17% increase in R&D efforts (thanks to the multitude of o